STOCK TITAN
  1. Home
  2. News
  3. IVVD

Invivyd to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Negative)
Tags
conferences
Rhea-AI Summary
Invivyd, Inc. to present at investor conferences
Positive
  • None.
Negative
  • None.

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will present at the following investor conferences:

H.C. Wainwright 25th Annual Global Investment Conference
Fireside Chat Date: Monday, September 11, 2023
Fireside Chat Time: 3:00 PM ET
Location: New York, NY

Morgan Stanley 21st Annual Global Healthcare Conference
Fireside Chat Date: Wednesday, September 13, 2023
Fireside Chat Time: 12:55 PM ET
Location: New York, NY

Live webcasts of the fireside chats will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 90 days following the events.

About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit https://invivyd.com/ to learn more.

Contacts:

Scott Young
(781) 208-1747
syoung@invivyd.com

Gabriella Linville-Engler
(781) 208-0160
gengler@invivyd.com


Stock IVVD logo
Invivyd Inc

NASDAQ:IVVD

IVVD Rankings

#4563 Ranked by Market Cap
#4901 Ranked by Stock Gains
N/A Ranked by Dividends

IVVD Latest News

Nov 9, 2023
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Nov 2, 2023
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights
Oct 31, 2023
Invivyd to Participate in Upcoming Investor Conferences
Sep 11, 2023
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 
Sep 5, 2023
Invivyd Appoints William Duke as Chief Financial Officer

IVVD Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link

About IVVD

adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020.